News

Adding capivasertib to fulvestrant was shown to improve the time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

Uproleselan plus chemotherapy missed the overall survival end point in the phase 3 trial assessing the combination in patients with relapsed/refractory acute myeloid leukemia.

Compared with physician’s choice of treatment, trastuzumab deruxtecan exhibited superior long-term survival and response rates in patients with HER2-positive breast cancer.

Oncology nurses can discuss dose modifications for common smoking cessation agents with patients and providers to improve smoking cessation rates.

Compared with chemotherapy alone, atezolizumab plus chemotherapy did not improve overall survival in select patients with early relapsing triple-negative breast cancer.

The accelerated approval of infigratinib has been withdrawn by the FDA for previously treated, FGFR2-positive, advanced cholangiocarcinoma.

A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.

The BLA for zenocutuzumab to treat NRG1-positive non–small cell lung cancer and pancreatic cancer received priority review from the FDA.

A biologics license application has been accepted by the FDA for subcutaneous nivolumab to treat adult patients eligible for approved solid tumor nivolumab indications

Enzalutamide with and without leuprolide improves rates of undetectable PSA levels compared with leuprolide alone in castration-sensitive prostate cancer.

Second-line venetoclax may lead to monthly cost savings vs second-line BTK inhibitor for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.

Tolerable anti-tumor activity was demonstrated in patients with HER2-overexpressing non–small cell lung cancer who were treated with trastuzumab deruxtecan at 2 dose levels.

Frontline treatment with pembrolizumab plus trastuzumab/chemotherapy significantly and meaningfully improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.

Lisocabtagene maraleucel was approved by the FDA to treat adults with relapsed/refractory follicular lymphoma who were treated with 2 or more prior lines of systemic therapy.

One of the first HPV self-collection solutions has been approved by the FDA, which can identify women at risk of developing cervical cancer.

Recent data from a phase 3b trial support venetoclax as a CLL treatment option for those with or without B-cell receptor–associated kinase inhibitor treatment.

Glecirasib resulted in durable responses with a manageable safety profile for pretreated advanced non-small cell lung cancer with KRAS G12C mutations.

The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.

Tiffany Bostwick, P.A., discussed the importance of communication and education around adverse effects for both oncology nurses and for patients with advanced endometrial cancer who are treated with immunotherapies.

Patients with triple-negative breast cancer with an increased TIL count in breast tissue were more likely to have an improved distant recurrence-free survival.

Dostarlimab plus chemotherapy has been granted priority review from the FDA to expand its indication to all adult patients with primary advanced or recurrent endometrial cancer.

The FDA granted fast track designation to CTX-009 plus paclitaxel for pretreated metastatic or locally advanced biliary tract cancer.

Meaghan Mooney, B.S.N., RN, OCN, discusses the steps she takes to be an extraordinary healer every day and offers advice for newer oncology nurses.

Patients with high-risk prostate cancer treated with apalutamide with androgen deprivation therapy following radical prostatectomy had a recurrence-free survival rate of 100% after 2 years.

Pembrolizumab plus chemotherapy did not improve disease-free survival in patients with newly diagnosed, high-risk endometrial cancer, missing the primary end point of the phase 3 KEYNOTE-B21 study.

Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.

Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.